Copyright
©The Author(s) 2022.
World J Gastrointest Oncol. Sep 15, 2022; 14(9): 1798-1807
Published online Sep 15, 2022. doi: 10.4251/wjgo.v14.i9.1798
Published online Sep 15, 2022. doi: 10.4251/wjgo.v14.i9.1798
Table 4 Diagnosis of advanced adenoma/sessile serrated lesion, advanced neoplasia and colorectal cancer as per time since previous colonoscopy
| Total = 1051 | Had a previous colonoscopy, n = 319 | Never had or uncertain of previous colonoscopy, n = 732 | ||||
| 0-4 yr, (n = 68) | 4-5 yr (n = 37) | > 5 yr (n = 204) | Unsure when (n = 10) | Never (n = 685) | Unsure (n = 47) | |
| AA-SSL | 7 (10.3%) | 7 (18.9%) | 41 (20.1%) | 1 (10%) | 181 (26.4%) | 19 (40.4%) |
| Advanced neoplasia | 7 (10.3%) | 8 (21.6%) | 44 (21.6%) | 1 (10%) | 202 (29.5%) | 19 (40.4%) |
| CRC | 0 | 1 (2.7%) | 3 (1.5%) | 0 | 37 (5.4%) | 1 (2.1%) |
- Citation: Rattan N, Willmann L, Aston D, George S, Bassan M, Abi-Hanna D, Anandabaskaran S, Ermerak G, Ng W, Koo JH. To scope or not - the challenges of managing patients with positive fecal occult blood test after recent colonoscopy. World J Gastrointest Oncol 2022; 14(9): 1798-1807
- URL: https://www.wjgnet.com/1948-5204/full/v14/i9/1798.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v14.i9.1798